Designing personalized therapy depends on IH tumor status, but research has confirmed the association of HER2 with a TP53 mutation, as well as the immunoheterogeneity of tumors with a PD-L1 status and high mutational diversity. This evidence concerns the gene TP53 and neoplasm.